Skip to main content

LCD L37130: MolDX: DecisionDx-UM (Uveal Melanoma)

LCD L37130, MolDX: DecisionDx-UM (Uveal Melanoma), is the Local Coverage Determination that CGS Administrators, LLC applies to claims from 2 states (KY, OH), effective 2025-05-22 and first in force 2017-07-10. The policy text runs 65 words, and its billing and coding article A56981 lists 6 ICD-10-CM codes that support medical necessity for 1 procedure code. 2 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 6 covered ICD-10-CM codes: the same total as L37033 (Palmetto GBA, 6 codes, revised 2022-06-30) and the same total as L37070 (Noridian Healthcare Solutions, LLC, 6 codes, revised 2026-01-22).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
CGS Administrators, LLC
States and territories
2
KY OH
Revision effective
2025-05-22
Original effective
2017-07-10
Policy text
65 words
Covered ICD-10 codes (articles)
6

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L37130
ContractContractorTypeStates
15102CGS Administrators, LLCMAC - Part BKY
15202CGS Administrators, LLCMAC - Part BOH
15101CGS Administrators, LLCMAC - Part AKY
15201CGS Administrators, LLCMAC - Part AOH

Billing and coding article A56981: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A56981 (Billing and Coding: MolDX: DecisionDx-UM (Uveal Melanoma)) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

A56981: Billing and Coding: MolDX: DecisionDx-UM (Uveal Melanoma) (Billing and Coding, effective 2023-11-16)

Covered ICD-10-CM codes
6
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
1
Full article
cms.gov record
First 6 covered ICD-10-CM codes in A56981
ICD-10-CMDescription (FY2027)
C69.31Malignant neoplasm of right choroid
C69.32Malignant neoplasm of left choroid
C69.41Malignant neoplasm of right ciliary body
C69.42Malignant neoplasm of left ciliary body
C69.91Malignant neoplasm of unspecified site of right eye
C69.92Malignant neoplasm of unspecified site of left eye

Procedure codes: 81552.

Coverage indications, limitations and medical necessity

This Medicare contractor will provide limited coverage for the DecisionDx-UM (Castle Bioscience, Inc.) test for the management of newly diagnosed uveal melanoma. This test is intended for the determination of metastatic risk, and to guide surveillance and referral to medical oncology (preferably an oncologist with expertise in melanoma) in patients who have a confirmed diagnosis of uveal melanoma (UM) and no evidence of metastatic disease.

Summary of evidence (opening)

UM is a rare cancer, affecting ~1600-1700 patients per year in the United States, but it is the most common intra-ocular cancer in adults. UM arises in the middle layer of the eye, the uvea tract, which consists of the iris, ciliary body, and choroid. Eye-sparing radiation (brachytherapy or proton beam therapy) is the most common treatment approach, but approximately 10% of patients will undergo enucleation due to large and/or aggressive tumors that cannot be managed with radiation or due to eye pain or vision loss. Local treatment by radiation or enucleation is highly successful at controlling the primary tumor, with only ~5% chance of local recurrence. Most patients present with local disease and no evidence of metastases, however, as many as 50% of patients will ultimately experience distant metastasis, most commonly to the liver.

Clinicopathologic staging cannot reliably identify patients at low or high risk of metastasis, as even early stage patients (AJCC Stage I-II) have a substantial risk of metastasis and mortality. Historically, most UM patients were managed with high intensity surveillance, including frequent imaging and laboratory tests, with the goal of diagnosing early metastasis. Systematic imaging has been shown to be effective at identifying asymptomatic metastases, which is important because treatment of liver metastases with surgical resection or regional therapy is more effective and achieves better outcomes when tumor burden is low. However, since approximately 50% of patients will not experience metastasis, a substantial proportion of patients were subjected to unnecessary imaging, laboratory tests, and clinical visits, resulting in patient burden, undo exposure to radiation and over-utilization of healthcare resources.

An accurate determination of metastatic risk at diagnosis allows for a risk-appropriate surveillance program. Patients at high-risk of metastasis can continue to be followed with a high intensity program as previously prescribed, such as quarterly ultrasound, magnetic resonance imaging (MRI) or computerized tomography (CT) scans alternating withliver function tests (LFTs), and consideration of adjuvant treatment. These patients benefit from early detection of metastatic disease when it can be most effectively treated. Patients with low metastatic risk can be removed from this traditional intensive surveillance and instead followed with a low intensity program, such as yearly exams, imaging, and LFTs.

DecisionDx-UM Test Description and Intended Use

The contractor cites 7 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2017-07-10
Current revision effective
2025-05-22
Last reviewed by the contractor
2025-05-05
MCD version
21

Other related documents: A55561 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the CGS Administrators, LLC hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L37130 cover?

This Medicare contractor will provide limited coverage for the DecisionDx-UM (Castle Bioscience, Inc.) test for the management of newly diagnosed uveal melanoma. This test is intended for the determination of metastatic risk, and to guide surveillance and referral to medical oncology (preferably an oncologist with expertise in melanoma) in patients who have a confirmed diagnosis of uveal melanoma (UM)… The full 65-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L37130 apply to?

CGS Administrators, LLC applies it to Medicare claims in 2 states: KY, OH. It binds only that contractor; 2 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L37130?

The companion billing and coding article A56981 lists 6 ICD-10-CM codes in 1 group that support medical necessity; the first 6 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L37130?

A denial under LCD L37130 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A56981's 6 covered diagnosis codes, then file a redetermination with CGS Administrators, LLC within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.